Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors [Phase 2]

View source ↗

Summary

Pazopanib hydrochloride is being studied in a Phase 2 trial for progressive carcinoid tumors (neuroendocrine tumors); the study status is active not recruiting …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neuroendocrine Tumor
• Foregut Neuroendocrine Tumor
• Hindgut Neuroendocrine Tumor
• Midgut Neuroendocrine Tumor
• Neuroendocrine Tumor
• Regional Digestive System Neuroendocrine Tumor

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-06-01